Famciclovir in chronic hepatitis B: Results of a dose-finding study

Journal of Hepatology

Volumn 32, Issue 6, 2000, Pages 1011-1018

  Trépo, Christian ^c   Jezek, Pavel ^a   Atkinson, Gillian ^b   Boon, Ron ^b   Young, Clarence ^b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b GLAXOSMITHKLINE   (United Kingdom)

^c MD   (France)

Author keywords

Alanine transferase; Chronic hepatitis B; Dose finding study; Famciclovir; HBV DNA; Nucleoside analogue; Seroconversion

Indexed keywords

ALPHA INTERFERON; FAMCICLOVIR; NUCLEOSIDE ANALOG; PLACEBO;

ABDOMINAL PAIN; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HEPATITIS B; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; SEROCONVERSION;

EID: 0343674497     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80106-3     Document Type: Article

References (27)

1. Lee WM. Hepatitis B viral infection. N Engl J Med. 337:1997;1733-1745.
2. Lok AS. Does interferon therapy for chronic hepatitis B reduce the risks of developing cirrhosis and hepatocellular carcinoma? Hepatology. 22:1995;1336-1338.
3. Hoofnagle JH, Di Bisceglie AM. Treatment of chronic viral hepatitis. N Engl J Med. 336:1997;346-356.
4. Heathcote J, Schalm SW, Cainciara J, Farrell G, Feinmann V, Sherman M, et al. Lamivudine and interferon alpha combination treatment in patients with chronic hepatitis B infection. J Hepatol. 28:(Suppl 1):1998;43.
5. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med. 119:1993;312-323.
6. Lai CL, Chien RN, Leung NWY, Chang T-T, Guan R, Tai D, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 339:1998;61-68.
7. Dienstag J, Schiff E, Wright T, Perrillo R, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 341:1999;1256-1263.
8. Lueng NWY, Lai CL, Chang T-T, Guan R, Lee CM, Ng KY, et al. Three year lamivudine therapy in chronic HBV. J Hepatol. 30:(Suppl 1):1999;59. Abstract GS5/25.
9. Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother. 4:(Suppl 1):1993;47-55.
10. Cirelli R, Herne K, McCrary M, Lee P, Tyring S. Famciclovir: review of clinical efficacy and safety. Antiviral Res. 29:1996;141-151.
11. Korba BE, Boyd MR. Penciclovir is a selective inhibitor of hepatitis B virus replication in human hepatoblastoma cells. Antimicrob Agents Chemother. 40:1996;1282-1284.
12. Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology. 24:1996;996-1002.
13. Dannaoui E, Trepo C, Zoulim F. Inhibitory effect of penciclovirtriphosphate on duck hepatitis B reverse transcription. Antiviral Chem Chemother. 8:1997;38-46.
14. Lin E, Luscombe C, Wang Y, Shaw T, Locarnini S. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 40:1996;413-418.
15. Main J, Brown JL, Howells C, Galassini R, Crossey M, Karayiannis P, et al. A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis viral infection. J Viral Hepat. 3:1996;211-215.
16. Wen LT, Henneberger M, Nguyen N, McPherson A. Quantification of hepatitis B virus DNA in serum by ammonium sulfate precipitation and molecular hybridization. J Clin Lab Anal. 8:1994;44-50.
17. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 75:1988;800-802.
18. Lok ASF. Antiviral therapy of the Asian patient with chronic hepatitis B. Semin Liver Dis. 13:1993;360-366.
19. Zoulim F, Trepo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol. 28:1998;1-8.
20. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 333:1995;1099-1105.
21. Boon RJ, Saltzman R, Atkinson GA. The clinical safety experience with famciclovir. [abstract] Hepatology. 24:(4 Pt 2):1996;282A.
22. Neuhaus P, Manns M, Atkinson G. Safety and efficacy of famciclovir for the treatment of recurrent hepatitis B in liver transplant recipients. [abstract] Hepatology. 26:(4 Pt 2):1997;260A.
23. Honkoop P, de Man RA, Heijtink RA, Schalm SW. Hepatitis B reactivation after lamivudine (letter). Lancet. 346:1995;1156-1157.
24. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology. 27:1998;1670-1677.
25. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol. 26:1997;1148-1153.
26. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
27. Cane P, Mutimer D, Ratcliffe D, Cook P, Beards G, Elias E, et al. Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antiviral Therapy. 4:1999;7-14.